AUS
NZ
UK
CA
USA
IND
Highlights
- Boutique funds in Australia excelled, surpassing larger investment players in Q3.
- Paragon's focus on commodities and Pengana’s healthcare-backed returns led gains.
- Emerging companies also showed strong performances, notably in tech and aquaculture.
Australian boutique funds have delivered significant returns in the third quarter, outperforming larger local investment firms. Leading the charge, Paragon’s Australian Long Short Fund achieved notable growth, largely driven by strategic moves in commodities. According to Morningstar’s report covering over 2,500 Australian investment strategies, Paragon posted nearly 41% returns, capitalizing on a surge in gold prices as interest rate cuts in the U.S. took hold.
Paragon’s Commodity Play and China’s Economic Stimulus Boost
Paragon's portfolio manager strategically increased the fund's exposure to gold prior to the Federal Reserve’s rate cuts, anticipating that the precious metal would benefit from the expected economic adjustments. Even as the U.S. implemented a half-point rate cut, Paragon continues its strong positioning in gold, with the fund manager projecting further gains in the sector.
Additionally, recent economic stimulus measures from China have bolstered returns, particularly in commodities like iron ore. Paragon’s leadership noted that this latest round of economic interventions by Beijing represents a substantial effort to boost demand. China, a key consumer of global resources, is expected to provide further momentum for commodities, as reflected in Paragon’s ongoing confidence in sectors like copper.
Pengana’s Strong Healthcare Performance
In second place, Pengana’s high conviction fund continued to shine, achieving a 30.9% quarterly return and a 12-month increase of 107%. A major contributor was biotech firm Clarity Pharmaceuticals (ASX:CU6), which saw a massive surge of over 600% in the last year. According to Pengana’s portfolio managers, healthcare investments drove significant growth, although the fund has since reduced its stake in Clarity Pharmaceuticals.
The fund’s largest holding now is in U.S.-based titanium recycling technology company IperionX (NASDAQ:IPX), which has shown strong momentum as demand for locally-sourced titanium rises. Pengana's management remains optimistic, reflecting on their successful historical investments in biotech and recycling technology, though the fund maintains a diversified stance to capitalize on evolving market dynamics.
Saville Capital’s Emerging Companies Fund
Saville Capital’s emerging companies fund, with a 25.8% quarterly return, rounds out the top three. This fund focuses on smaller-cap companies in Australia and New Zealand, primarily those outside major indexes like the S&P/ASX 100. With holdings in tech firms such as building technology provider FBR and aquaculture enterprise Murray Cod Australia, Saville has leveraged a recovery in smaller companies, supported by favorable macroeconomic factors. Anticipated rate cuts by the Reserve Bank of Australia are expected to further benefit these types of investments, providing additional liquidity and growth opportunities within the micro-cap segment.
Additional Boutique Fund Performances
Other boutique funds also saw strong returns, notably within the property sector, which benefited from expectations of rate cuts. First Sentier’s Geared Global Property Securities Fund and SG Hiscock’s SGH Property Income Fund emerged as top performers, reflecting the general strength of active management in the Australian market in 2024. Notably, S&P data showed Australian active managers outperforming passive ones, especially in mid and small-cap funds, where performance disparities have been more pronounced.
